These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35135148)

  • 1. ALK Testing Trends and Patterns Among Community Practices in the United States.
    Illei PB; Wong W; Wu N; Chu L; Gupta R; Schulze K; Gubens MA
    JCO Precis Oncol; 2018 Nov; 2():1-11. PubMed ID: 35135148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.
    Lin HM; Wu Y; Yin Y; Niu H; Curran EA; Lovly CM; Humphries MJ
    Clin Lung Cancer; 2023 Jan; 24(1):e39-e49. PubMed ID: 36376172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers.
    Bernicker EH; Xiao Y; Abraham A; Yang B; Croix DA; Redpath S; Engstrom-Melnyk J; Shah R; Madala J; Allen TC
    Oncologist; 2021 Jun; 26(6):e1050-e1057. PubMed ID: 33823082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices.
    Wong W; Wu N; Gupta R; Mansfield AS
    Clin Lung Cancer; 2021 May; 22(3):e470-e480. PubMed ID: 32763067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
    Guérin A; Sasane M; Zhang J; Macalalad AR; Galebach P; Jarvis J; Kageleiry A; Culver K; Wu EQ; Wakelee H
    Cancer Epidemiol; 2015 Jun; 39(3):307-12. PubMed ID: 25914136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
    Lee DH; Tsao MS; Kambartel KO; Isobe H; Huang MS; Barrios CH; Khattak A; de Marinis F; Kothari S; Arunachalam A; Cao X; Burke T; Valladares A; de Castro J
    PLoS One; 2018; 13(8):e0202865. PubMed ID: 30148862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data.
    Allen TC; Xiao Y; Yang B; Croix D; Abraham A; Redpath S; Engstrom-Melynk J; Shah R; Madala J; Bernicker EH
    Oncotarget; 2021 Nov; 12(23):2308-2315. PubMed ID: 34786182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
    Davies J; Martinec M; Coudert M; Delmar P; Crane G
    Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
    Jahanzeb M; Lin HM; Pan X; Yin Y; Baumann P; Langer CJ
    Clin Lung Cancer; 2021 Jan; 22(1):49-57. PubMed ID: 33250347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand.
    McKeage MJ; Tin Tin S; Khwaounjoo P; Sheath K; Dixon-McIver A; Ng D; Sullivan R; Cameron L; Shepherd P; Laking GR; Kingston N; Strauss M; Lewis C; Elwood M; Love DR
    Intern Med J; 2020 Jun; 50(6):716-725. PubMed ID: 31318119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns for Advanced Non-Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice.
    McKay C; Burke T; Cao X; Abernethy AP; Carbone DP
    Clin Lung Cancer; 2016 Sep; 17(5):449-460.e7. PubMed ID: 27157534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Sheinson D; Wong WB; Wu N; Mansfield AS
    Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
    Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
    Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
    Velcheti V; Hu X; Piperdi B; Burke T
    Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
    Sauter JL; Butnor KJ
    Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.